These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1457284)

  • 1. Treatment of systemic sclerosis.
    Wigley FM
    Curr Opin Rheumatol; 1992 Dec; 4(6):878-86. PubMed ID: 1457284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.
    Rook AH; Freundlich B; Jegasothy BV; Perez MI; Barr WG; Jimenez SA; Rietschel RL; Wintroub B; Kahaleh MB; Varga J
    Arch Dermatol; 1992 Mar; 128(3):337-46. PubMed ID: 1550365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systemic scleroderma in children].
    Plantin P; Gavanou J; Le Fur JM; Guillet G
    Arch Fr Pediatr; 1988 Dec; 45(10):805-8. PubMed ID: 3266459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of systemic sclerosis in childhood complicated by severe digital ulcers].
    Falcini F; Volpi M; Pierattelli M; Taccetti G; Pratesi G; Matucci Cerinich M
    Pediatr Med Chir; 1984; 6(5):703-7. PubMed ID: 6535137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis.
    Ng SC
    Singapore Med J; 1992 Apr; 33(2):189-92. PubMed ID: 1621127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of systemic sclerosis.
    Medsger TA
    Rheum Dis Clin North Am; 1989 Aug; 15(3):513-31. PubMed ID: 2672135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of systemic sclerosis.
    Steen VD
    Am J Clin Dermatol; 2001; 2(5):315-25. PubMed ID: 11721650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of oral methotrexate in the treatment of systemic sclerosis.
    Krishna Sumanth M; Sharma VK; Khaitan BK; Kapoor A; Tejasvi T
    Int J Dermatol; 2007 Feb; 46(2):218-23. PubMed ID: 17269983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systemic sclerosis].
    Tamborrini G; Distler M; Distler O
    Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].
    Jimenez SA; Sigal SH
    J Rheumatol; 1991 Oct; 18(10):1496-503. PubMed ID: 1765974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.